MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- AJANTA PHARMA
AJANTA PHARMA Share Price 
(AJPH)
Here is the latest stock price and chart of AJANTA PHARMA. For more details, see the AJANTA PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Discover: The 5-Minute Blueprint for Becoming a ONE STOCK CROREPATI
| Live BSE Quotes | Jul 7, 2022 01:46:00 PM | ||
|---|---|---|---|
| Price (Rs)1,190.15 | Open (Rs) 1,199.70 | High (Rs) 1,199.95 | Low (Rs) 1,173.05 |
| % Change-0.07 | Volume 1,633 | Value (Rs) 1,943,515 | 52-Week H/L 1,613.33 / 1,062.20 |
| Live NSE Quotes | Jul 7, 2022 1:49:58 PM | ||
|---|---|---|---|
| Price (Rs)1,184.50 | Open (Rs) 1,194.00 | High (Rs) 1,201.05 | Low (Rs) 1,172.00 |
| % Change-0.77 | Volume 49,853 | Value (Rs) 59,144,104 | 52-Week H/L 1,623.33 / 1,061.77 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -0.07% | 1 Month 3.43% | 3 Months 2.72% | 1 Year -17.56% | 5 Years (CAGR)* 2.88% | 10 Years (CAGR)* 34.28% |
* Compound Annual Growth Rate
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 55.62 | P/E Ratio (x) 21.40 | Market Cap (Rs m) 152,488.21 | P/BV (x) 4.78 | Dividend Yield (%) 0.80 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
AJANTA PHARMA Share Price Today:
AJANTA PHARMA last traded price was down 0.1% to Rs 1,190.2 on the BSE. On the NSE, AJANTA PHARMA last traded price was down 0.8% to Rs 1,184.5. The total volume of shares traded was 0.1 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.6%. And the benchmark S&P BSE SENSEX was at 54,154.7 (up 0.8%).
Over the last 30 days, the AJANTA PHARMA share price is up 3.1%. And over the last one year, AJANTA PHARMA share price is down 17.1%.
The current market capitalisation of AJANTA PHARMA stands at Rs 152,488.21 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of March 2022, promoter pledging in AJANTA PHARMA stands at 16.60%. To know more, check out the latest shareholding pattern of AJANTA PHARMA.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
FAQs on AJANTA PHARMA
What is the AJANTA PHARMA share price today?
The last traded price of AJANTA PHARMA was Rs 1,190.2 on the BSE, down 0.1% over the previous close. On the NSE, AJANTA PHARMA last traded price was down 0.8% at Rs 1,184.5.
What is the market cap of AJANTA PHARMA?
The current market capitalisation of AJANTA PHARMA stands at Rs 152,488 m.
What is the Earnings per share (EPS) of AJANTA PHARMA?
AJANTA PHARMA had an EPS of Rs 55.6 in the latest financial year. In the most recent quarter, the company declared an EPS of Rs 11.8.
What is the PE Ratio and PB Ratio of AJANTA PHARMA?
What is the Dividend Yield of AJANTA PHARMA?
For the financial year 2021, AJANTA PHARMA declared dividend amounting to Rs 9.5 per share. At the current price of Rs 1,190.2, this results in a dividend yield of 0.8%.
Today's Market
Sensex Zooms 400 Points, Nifty Trades Above 16,000; Titan Rallies 6%(10:30 am)
Asian share markets mostly opened higher today after minutes from a Federal Reserve meeting showed that US central bankers are determined to fight inflation despite recession worries.
Related Views On News
Pharma Company to Issue Bonus Shares this Week. Are you Eligible? (Views On News)
Jul 4, 2022The company has also announced a final dividend of Rs 23 per equity share recently.
5 Takeaways from Sun Pharma's Q4 Results (Views On News)
May 30, 2022It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Why Divi's Lab Share Price is Falling (Views On News)
May 24, 2022Here's why Divi's Lab's stock fell over 10% in two days.
Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)
May 23, 2022For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)
May 19, 2022During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsMost Popular
5 Indian Companies where Mutual Fund Holdings are Consistently Increasing (Views On News)
Jul 1, 2022Mutual funds are buying shares at a time when FIIs are consistently selling. Here are 5 stocks where MF holdings has increased for the past 4 quarters.
Auto Stocks are in the Fast Lane. Is it Time to Buy? (Profit Hunter)
Jun 23, 2022The auto index is outperforming the Nifty by a mile. Have auto stocks finally bottomed out?
Forget FIIs. Follow These Experts to Navigate the Market (Profit Hunter)
Jun 24, 2022How you deal with the recent correction is going to be a great differentiator in your net worth.
Why Crude Oil Price is Falling (Views On News)
Jun 25, 2022Global markets have become volatile, sending chills through the crude oil market.
The 4 Strongest Companies in the Tata Group. Add Them to Your Watchlist (Views On News)
Jun 30, 2022Check out these four Tata group companies that have the strongest performance and fundamentals.
MoreOUR TOP 5 IDEAS
TRACK AJANTA PHARMA
- Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AJANTA PHARMA
AJANTA PHARMA - ADCOCK INGRAM COMPARISON
COMPARE AJANTA PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks in 2022
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.